Unlock stock picks and a broker-level newsfeed that powers Wall Street.

16 Best Meal Delivery Services for Weight Loss

In This Article:

This article will look at the 16 best meal delivery services for weight loss. If you want to skip our detailed analysis of the anti-obesity drug market, head to the 5 Best Meal Delivery Services for Weight Loss.

The prevalence of obesity—a medical condition in which a person has a Body Mass Index (BMI) of 30 or more— is a significant health concern in the United States. This is due to the fact that carrying extra fat can lead to major health issues like type 2 diabetes, heart disease, some cancers, and osteoarthritis.

41.9% of adults in the U.S. are obese, according to data gathered by the Centers for Disease Control and Prevention (CDC) between 2017 and 2020. Additionally, obesity costs the nation’s healthcare system close to $173 billion annually.

Meanwhile, the anti-obesity drug market is assisting people in achieving a healthy weight, which enhances their quality of life in general. According to a report by Fortune Business Insights, the anti-obesity drug market was valued at $2.82 billion in 2022. The market is anticipated to grow from $4.51 billion in 2023 and expand at a compound annual growth rate of 26.1% from 2023 to 2030, reaching a value of $22.85 billion at the conclusion of the predicted period.

The report states that per CDC data, there are more than 650,000 cases of obesity-related cancers each year in the U.S. The key factors influencing the market's expansion are greater understanding of the risks of this chronic disease and the costs associated with it, hence leading to greater acceptance of therapies for early and preventative management of the condition along with the escalating prevalence of other chronic illnesses.

Moreover, we previously reported that a recent survey from The Kaiser Family Foundation (KFF) revealed that almost half of Americans (45%) were interested in using weight-loss drugs like Ozempic, Wegovy, and Mounjaro.

Don’t Miss: 11 Best Weight Loss Stocks to Invest In

Novo Nordisk A/S (NYSE:NVO), a Danish company,  markets injectable semaglutide under the brand names Ozempic and Wegovy. Given that it includes a greater amount of semaglutide (2.4 mg), only Wegovy, has received FDA approval for the treatment of obesity.

This August, Novo Nordisk A/S (NYSE:NVO) made headlines when it revealed that a weekly dose of 2.4 mg of Wegovy (semaglutide) reduced the risk of a major adverse cardiovascular event by 20% over the course of a five-year study called Select. A total of 17,604 people aged 45 years or older, who were overweight or obese, had established cardiovascular disease (CVD), and no prior history of diabetes, took part in the study.